# Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients

> **NCT00427635** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00427635
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427635, "Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00427635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*